Kymera Therapeutics Inc. has patented new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 1 (IRAK-4)-targeting moiety via linker.

Astrazeneca AB patents describe new proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety reported to be useful for the treatment of cancer.

Scientists at Apichope Bio Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker acting as IRAK-4 degradation inducers.

Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a target protein binding moiety through a linker reported to be useful for the treatment of cancer, dermatological, neurological, respiratory and cardiovascular disorders, autoimmune diseases, infections and transplant rejection, among others.

Shenogen Pharma Group Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an estrogen receptor α (ER-α; ESR1)-targeting moiety through a linker reported to be useful for the treatment of cancer, infections, immunological disorders, diabetes, inflammatory and cardiovascular disorders.

Shanghai Huilun Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker.

Biopolar Hongye (Nantong) Pharmaceutical Co., Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) binding moiety reported to be useful for the treatment of cancer, inflammatory and autoimmune diseases.

Several recent Celgene Corp. patents detail the development of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety via a linker.

Foghorn Therapeutics Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising ubiquitin ligase binding moieties covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety reported to be useful for the treatment of cancer and viral infection.

TYK Medicines Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently bonded to an EGFR (mutant)-targeting moiety through a linker.